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ABSTRACT 
Posterior cortical atrophy (PCA) is an understudied visual impairment syndrome most often due to 
“posterior Alzheimer’s disease (AD)” pathology. Case studies detected mutations in PSEN1, PSEN2, 
GRN, MAPT and PRNP in subjects with clinical PCA. To detect the frequency and spectrum of 
mutations in known dementia genes in PCA, we screened 124 European-American subjects with 
clinical PCA (n=67) or posterior AD neuropathology (n=57) for variants in genes implicated in AD, 
frontotemporal dementia, and prion disease using NeuroX, a customized exome array. Frequencies 
in PCA of the variants annotated as pathogenic or potentially pathogenic were compared against 
~4,300 European-American population controls from the NHLBI Exome Sequencing Project (ESP). 
We identified two rare variants not previously reported in PCA, TREM2 Arg47His and PSEN2 
Ser130Leu.  No other pathogenic or potentially pathogenic variants were detected in the screened 
dementia genes. In this first systematic variant screen of a PCA cohort, we report two rare mutations 
in TREM2 and PSEN2, validate our previously reported APOE ε4 association, and demonstrate the 
utility of NeuroX. 
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1. INTRODUCTION  
Posterior cortical atrophy (PCA) was first described by Benson et al. (Benson et al., 1988) as 
a syndrome characterized by predominant visual deficits in the absence of primary ocular disease, 
and relative preservation of episodic memory and insight early in the disorder (Crutch et al., 2012). 
Its features often reflect involvement of posterior brain regions, and include some or all of these 
clinical features: Components of Bálint’s or Gerstmann syndromes, alexia, constructional dyspraxia, 
environmental disorientation, ideomotor apraxia, prosopagnosia or visual field defects. 
Neuropathologic series of PCA revealed AD pathology in 80-100% of cases (Ala et al., 1996; Alladi 
et al., 2007; Renner et al., 2004; Tang-Wai et al., 2004; Victoroff et al., 1994). Additionally, amyloid 
neuroimaging (de Souza et al., 2011; Lehmann et al., 2013; Rosenbloom et al., 2011) and 
cerebrospinal fluid (de Souza et al., 2011; Seguin et al., 2011) biomarkers of PCA subjects follow 
patterns similar to those in AD. Although the type of neuropathology in PCA is the same as that in 
typical AD, the distribution of the neuropathology is distinct. Both PET-amyloid imaging 
(Rosenbloom et al., 2011) and neuropathology studies suggest similarities in the regional distribution 
of the amyloid pathology between PCA and typical AD, but a strikingly greater burden of 
neurofibrillary tangle pathology in posterior brain regions in PCA subjects as compared to typical 
AD (Crutch et al., 2012). Thus, PCA is considered an atypical form of AD, although other 
pathologies, including Creutzfeldt-Jakob disease, corticobasal degeneration or Lewy body disease 
can also rarely present as PCA (Renner et al., 2004; Tang-Wai et al., 2004).  
Given its distinct clinical presentation and limited heterogeneity in etiology with AD as the 
main underlying neuropathology, uncovering the genetics of PCA is important as it can identify 
genetic factors that are both common with and distinct from those in typical AD, hence providing 
insight about pathophysiology of both conditions. Further, given that the onset age for PCA is 
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generally younger, thus often prompting clinical genetic screens, discovery of the full pathogenic 
mutation spectrum that can lead to PCA can aid the clinician in the choice of genetic tests. To date, 
there are only case reports of PCA subjects with missense variants in genes previously implicated in 
early-onset AD (EOAD) (Saint-Aubert et al., 2013; Sitek et al., 2013; Tremolizzo et al., 2014), 
frontotemporal dementia (FTD) (Caroppo et al., 2015; Rossi et al., 2014), and Creutzfeldt-Jakob 
disease (CJD) (Depaz et al., 2012).  
In this first systematic mutation screen of 124 subjects with clinical PCA or posterior AD 
pathology, we utilized a customized Illumina exome genotyping array, NeuroX, to evaluate genes 
known to harbor pathogenic variants in EOAD [APP (Goate et al., 1991), PSEN1 (Sherrington et al., 
1995) and PSEN2 (Rogaev et al., 1995)], LOAD [APOE (Yu et al., 2014) and TREM2 (Guerreiro 
and Hardy, 2013; Kleinberger et al., 2014)], FTD [GRN (Perry et al., 2013; Wojtas et al., 2012) and 
MAPT (Carney et al., 2014; Wojtas et al., 2012), and CJD [PRNP (Guerreiro et al., 2014)], for their 
role in PCA. NeuroX is enriched for risk variants involved in neurological disorders, thus providing 
an efficient platform for rapid screening of genes of interest (Ghani et al., 2015). Our findings have 
implications for the mutation spectrum in PCA as well as the utility of NeuroX. 
  
2. MATERIALS AND METHODS 
2.1. Subjects 
All subjects were recruited at Mayo Clinic Jacksonville in Florida or Mayo Clinic Rochester 
in Minnesota. Sixty seven subjects had clinical diagnosis of PCA, five of whom also had pathologic 
diagnosis; and 57 had neuropathological diagnosis as posterior AD, but not a clinical diagnosis 
(Table 1). Clinical diagnosis of PCA was made according to published core criteria (Tang-Wai et 
al., 2004) as follows: presentation of visual complaints in the absence of significant primary ocular 
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disease; relative preservation of anterograde memory and insight early in the disorder; insidious 
onset and gradual progression; disabling visual impairment throughout the disorder; absence of 
stroke or tumor; absence of early parkinsonism and hallucinations. All subjects with pathologic 
diagnoses were evaluated by one neuropathologist (DWD). For the neuropathologic diagnosis, senile 
plaques (per 10 x field) and neurofibrillary tangles (NFT) (per 40 x field) are counted in the mid-
frontal, superior temporal, inferior parietal, motor, visual (Brodmann’s area 17=BA 17) and 
entorhinal cortices, in addition to two sectors of the amygdala. NFTs are also counted in the nucleus 
basalis of Meynert. Visual association cortex (BA 18) is also scanned in all cases and counted in 
those with severe NFT pathology. All subjects with neuropathologic diagnosis of posterior AD have 
disproportionate severity of NFT in BA17 and BA18 compared to typical AD cases, but could have 
additional pathologies including Lewy bodies, vascular disease, hippocampal sclerosis or 
progressive supranuclear palsy. The overall pattern of NFT severity in BA17 and BA18 is greater 
than that in the frontal cortex in posterior AD, such that this diagnosis is not simply a function of the 
overall disease severity, but reflects disproportionate, focal involvement of the visual cortices. Thus, 
subjects with posterior AD had neuropathology characteristics of PCA (Crutch et al., 2012). The 
disproportionate involvement of the posterior cortices was not determined by objective criteria, but 
subjectively. All neuropathologically diagnosed cases had Braak stage of 5.5 or 6, except for one 
patient with a Braak stage of 4. Our rationale for including posterior AD cases in our cohort stems 
from prior neuropathologic studies of PCA, which consistently identified higher tangle counts in 
posterior cortical regions (Crutch et al., 2012). Only subjects with complete age, sex, ethnicity and 
APOE genotype information are included in the study.  
2.2. Analysis of NeuroX genotypes 
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One hundred and twenty four PCA samples were genotyped using the NeuroX, which is a 
customized Human Exome BeadChip (Illumina, Inc., San Diego, CA) containing 242,901 variants 
from the standard Illumina exome content, and an additional 24,706 custom content variants 
focusing on neurologic diseases (Nalls et al., 2015). It should be noted that since NeuroX is a 
commercially available array with predetermined content, not all known dementia gene variants that 
meet the inclusion criteria used in our study are present on this array, as described below in more 
detailed and as shown in Table 2. Variant clustering and genotyping was achieved using Illumina’s 
GenomeStudio software v2011.1 and the genotyping module v1.9.4. The CHARGE cluster file v1.0 
(Grove et al., 2013) was used to cluster the standard content, and the remaining variants were 
clustered using GenomeStudio’s clustering algorithm. All variants with a GenTrain Score < 0.7 had 
their clusters visually assessed and manually adjusted where appropriate. Any variants that were 
impossible to cluster or showing irregularities were zeroed. All genotype calls were exported to 
PLINK (Purcell et al., 2007) format in the forward orientation, and the resulting dataset was 
subjected to quality control using PLINK v1.07. Variants with greater than 10% missing data were 
excluded, resulting in 265,525 remaining variants with an average call rate of 99%. All samples had 
call rates above 99%.  
As the goal of this study was to evaluate the contribution to PCA of known disease-
associated variants in known dementia genes, we focused on variants that were previously reported 
in dementia patients, and for which there was evidence in the literature of pathogenicity either 
through their segregation with disease in families and/or through evaluation of their biological 
consequences at the molecular level. Therefore, we evaluated in this study only those variants that 
were annotated in the AD and FTD mutation database (AD&FTDMDB) (Cruts et al., 2012) as 
“pathogenic” or “pathogenic nature unclear”, in addition to variants in the Human Prion Protein 
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(HPP) Mutation Database (http://www.mad-cow.org/prion_point_mutations.html, both accessed on 
12/01/2014) which were annotated as “causative”, as well as the well-established AD risk missense 
variants in APOE (Cys112Arg, a.k.a APOE ε4) and TREM2 (Arg47His). Of the 415 variants 
(SNPs/insertions/deletions) in APP, PSEN1, PSEN2, APOE, TREM2, GRN, MAPT and PRNP that 
met these criteria, NeuroX contains assays for 117, of which 115 passed the genotype QC described 
above (Table 2). Although we used the annotation provided by the AD&FTDMDB (“pathogenic” or 
“pathogenic nature unclear”) for our variant selection criteria, in this study we make a distinction 
between pathogenic variants that are “deterministic” (sufficient to cause disease), versus variants 
that were demonstrated to be “risk factors” (variants that increase the risk of disease, but which are 
neither necessary nor sufficient to cause the disease) based on published data.  
 To date, there are six case reports of PCA patients with mutations in known dementia genes 
(Caroppo et al., 2015; Depaz et al., 2012; Rossi et al., 2014; Saint-Aubert et al., 2013; Sitek et al., 
2013; Tremolizzo et al., 2014). Of these six variants, four (PSEN1 G223R, PSEN2 M239I, MAPT 
V363I, and GRN R110X) are listed in the AD&FTDMUTDB, as “pathogenic”, but only PSEN2 
M239I is included on the NeuroX array. PSEN1 I211M is not on the AD&FTDMUTDB or in 
NeuroX. While the PRNP 120bp insertion from the published PCA case report is listed in the HPP 
mutation database, annotation of causality is not provided, and it was not present on NeuroX. 
Sanger sequencing was used to validate the NeuroX genotypes that were indicative of the 
presence of a variant of interest. Validated variants were formally tested for association with the risk 
of PCA with a Fisher’s exact in RStudio v0.98.1091 using counts from the Exome Variant Server’s 
European-American cohort as controls (http://evs.gs.washington.edu/EVS/, accessed on 
12/01/2014). Using simulation-based power calculations we have an estimated 80% power to detect 
a minimum odds ratio (OR)=1.45 from a variant with MAF=30%, similar to the effect size and MAF 
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of AD risk variants detected in our previous study (Carrasquillo et al., 2014). We are also powered to 
detect variants with an OR≤3.70 and MAF≥1%, and rarer variants with MAF≥0.1% and OR≤15. 
Linkage disequilibrium between APOE ε4 and its NeuroX proxy (rs769449) was evaluated in 
Haploview 4.0 (Barrett, 2009) using the  NeuroX rs769449 data and pre-existing APOE ε4 
genotypes in this cohort (Carrasquillo et al., 2014).   
  
3. RESULTS 
3.1. Variant screen in PCA 
 We assessed 124 subjects in our cohort, 67 of whom were diagnosed as PCA clinically and 
57 with posterior AD neuropathology (Table 1). There was no difference in the sex composition 
between the clinically and pathologically diagnosed subjects although APOE ε4 frequency was 
higher in posterior AD (0.46) compared with clinical PCA (0.30), as we previously reported in a 
slightly larger cohort including these 124 subjects (Carrasquillo et al., 2014). Notably, the APOE ε4 
frequency in both subgroups is enriched compared to control frequencies (0.12). The significant 
difference in mean age is explained by the use of age-at-onset for the clinical PCA subjects and age-
at-death for posterior AD cases. 
 Our NeuroX variant screen of 124 PCA subjects identified one rare pathogenic variant 
(TREM2 Arg47His) and one rare potentially pathogenic variant (PSEN2 Ser130Leu) (Table 3). Both 
of these rare variants are in genes known to be involved in AD, and were confirmed by Sanger 
sequencing (Figure 1). Neither variant has been previously reported in a PCA patient. 
Although NeuroX genotypes also identified a rare pathogenic GRN frameshift mutation, 
Gln130fs, Sanger sequencing did not confirm this variant and instead revealed a non-pathogenic, 
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synonymous variant, rs25646 (Asp128), indicating an error in the annotation and/or design of this 
NeuroX assay. This error has also been previously noted by others (Ghani et al., 2015).  
 The common APOE ε4 (rs429358) pathogenic variant could not be genotyped on the NeuroX 
given that it failed genotype cluster QC, as also previously noted (Ghani et al., 2015). Nevertheless, 
the genotypes for a strong APOE ε4 proxy (rs769449; D’=1.0, r2=0.80) on the NeuroX, 
demonstrated highly significant association with risk of PCA (124 PCA vs. 4,300 European-
American controls, Fisher’s exact OR= 4.24, p=1.5x10-19), as expected (Carrasquillo et al., 2014). 
No other pathogenic or potentially pathogenic variants were found in this screen. 
3.2. Description of the TREM2 Arg47His carrier 
The TREM2 Arg47His variant was found in a subject with posterior AD pathology. There 
was no detailed clinical data available on this female patient, who had onset of symptoms at age 71,  
a rather long disease duration (14 years) and APOE ε3/ε4 genotype. Brain weight was 1,020 grams 
with cortical atrophy demonstrating occipital predominance on gross anatomy. Figures 2 a and b 
depict the lateral and medial views, respectively, of gross anatomy of the brain from this subject 
where the occipital lobe atrophy is evident. The gap between the dorsal cerebellar surface and the 
ventral occipital lobe surface is especially notable in Figure 2b, which further demonstrates the 
occipital atrophy.   
There was advanced AD pathology in the posterior brain regions with Thal phase = 5 and 
Braak stage = 6. Thioflavin-S staining of senile plaques and neurofibrillary tangles shows severe 
neurofibrillary tangle pathology in the visual association cortex (BA18) (Figure 2c), but less dense 
pathology in the frontal cortex, hippocampus and basal nucleus of Meynert (Figures 2d-f). There 
was also TDP-43, Type 1 pathology and secondary pathologic diagnoses of hippocampal sclerosis 
and vascular disease in this patient.  
 PAGE 10 
For comparison, the same regions of a patient with typical AD neuropathology are shown in 
Figures 2g-j. The typical AD subject was matched to the posterior AD patient for Thal phase, Braak 
stage and gender; was also Caucasian and had age at death of 82. Brain weight of the typical AD 
subject was 920 grams, with less severe neurofibrillary tangle pathology in BA18 (Figure 2g), but 
more severe pathology in the frontal cortex, hippocampus and basal nucleus of Meynert (Figures 
2h-j). Hence, the disproportionate involvement of the posterior cortical regions is evident in the 
posterior AD subject. 
 
3.3. Description of the PSEN2 Ser130Leu carrier 
 The PSEN2 Ser130Leu variant was found in a clinically diagnosed female PCA patient, who 
at age 41 presented with a three year history of progressive visuospatial impairment with no memory 
difficulties at the time. Her symptoms started as prosopagnosia and difficulty reading her computer 
screen despite progressively increasing the font size. She was prescribed reading glasses with no 
benefit. She then developed difficulties understanding spatial relationships as manifested by 
problems with dressing, driving and putting a complex visual scene together. Her neurological 
examination showed Kokmen short test of mental status (STMS) score of 35/38 with impairment in 
drawing a clock face, copying a cube and calculation. Simultanagnosia and prosopagnosia were also 
noted on the exam with no ocular apraxia or optic ataxia. Visual acuity was intact (20/30) bilaterally. 
She had saccadic eye pursuits.  There was no evidence of parkinsonism and the rest of her 
neurological examination was unremarkable. Neuropsychological assessment revealed severe visual 
agnosia, intact attention and verbal memory with relative sparing of language abilities. Follow-up 
examination after a year of  her initial evaluation revealed a decline in her STMS (25/38), elements 
of Gerstmann syndrome with mild finger agnosia, right-left confusion, agraphia and acalculia; left 
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visual field neglect, left apraxia, left greater than right diffuse increase in deep tendon reflexes, and 
bilateral cortical sensory loss with astereognosis bilaterally. Interim decline in visuospatial 
impairment along with new-onset word finding difficulties were reported with no decline in episodic 
memory. On repeat neuropsychometric evaluation, she was unable to perform any of the visual tasks 
involving Benton Facial Recognition, Famous Faces, Visual Form Discrimination, and Boston 
Naming. There was mild decline in verbal fluency while logical memory skills remained relatively 
stable. Comprehensive laboratory workup including but not limited to serum paraneoplastic panel, 
thyroperoxidase antibody, ceruloplasmin, autoimmune markers (c-ANCA, p-ANCA, ANA, ENA, 
rheumatoid factor), vitamin B12, TSH, complete blood count; cerebrospinal fluid (CSF) studies 
including Whipple, Lyme, Borrelia burgdorferi PCR, glucose, protein, cell count, 14-3-3 protein 
level were unremarkable. Magnetic Resonance Imaging (MRI) of the brain at initial presentation 
showed diffuse mild cortical atrophy, more prominent in the right temporo-parieto-occipital region. 
Single voxel spectroscopy demonstrated decrease of N-acetylaspartate (NAA) in the right parieto-
occipital white matter. MRI re-imaging a year later showed similar findings. 18F-fluorodexyglucose 
positron emission tomography (FDG-PET) showed decreased metabolism in the corresponding 
areas, along with left temporoparietal hypometabolism to a lesser extent. Her clinical diagnosis was 
Probable Posterior Cortical Atrophy. This subject also had APOE ε3/ε4 genotype. 
  
4. DISCUSSION   
In this systematic mutation screen of known dementia genes in 124 subjects with clinical 
PCA or posterior AD pathology, we investigated 115 variants that have been categorized in 
AD&FTD (Cruts et al., 2012) or HPP mutation databases as “pathogenic”, “pathogenic nature 
unclear” or “causative”.  These variants were selected because they resided in one of the eight genes 
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that have variants that lead to or unequivocally increase risk for AD (APP, PSEN1, PSEN2, APOE, 
TREM2), FTD (MAPT, GRN) or CJD (PRNP); and also because they reside on the NeuroX chip and 
passed QC. We identified one rare pathogenic variant (TREM2 Arg47His) and one rare potentially 
pathogenic variant (PSEN2 Ser130Leu). Although the APOE ε4 allele could not be successfully 
genotyped with the NeuroX, we were able to detect highly significant association with a different 
APOE variant on the NeuroX (rs769449, p=1.5x10-19) that is in near perfect linkage disequilibrium 
with APOE ε4 (D’=1.0, r2=0.80), thus serving as an excellent proxy for APOE ε4, and confirming 
the highly significant APOE ε4 association with PCA that we had previously reported (Carrasquillo 
et al., 2014). 
 Until recently, mutation screens in PCA have been limited to case reports which identified 
PSEN1 I211M (Sitek et al., 2013), PSEN1 G223R (Saint-Aubert et al., 2013), PSEN2 M239I 
(Tremolizzo et al., 2014), MAPT V363I (Rossi et al., 2014),  GRN R110X (Caroppo et al., 2015), in 
addition to a family with PCA phenotype in which a 120 base pair octapeptide repeat insertion 
mutation was identified within PRNP (Depaz et al., 2012). A mutation screen of known dementia 
genes in a cohort of 227 early-onset probable AD subjects revealed PSEN1 P218L and PSEN1 
I238M mutations in two subjects with memory and vision loss, although this was not a specific 
screen for PCA (Wojtas et al., 2012). These studies highlight the mutation spectrum in AD, FTD and 
CJD genes which can lead to the clinical presentation of PCA. Amongst these eight reports, five 
pertain to AD genes, although it is difficult to make inferences regarding mutation frequency based 
on case reports. 
  Our study is useful in that it provides estimations of the type and frequency of such 
mutations in PCA given that it is a sizable cohort rather than a case report. Both rare variants 
identified in our study are in AD genes (PSEN2 and TREM2), which is consistent with the finding 
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that much of PCA etiopathology is attributed to AD. Since two out of 124 screened subjects had a 
coding variant, we can estimate that 1.6% of PCA subjects harbor such a variant, likely in an AD 
gene. However, it must be noted that this is likely an underestimate, considering that our screen was 
limited to variants present in the NeuroX. In addition, as we have not imposed any age restrictions in 
our cohort, this estimate is likely to be higher amongst the younger PCA subjects.  
This is the first identification of the TREM2 Arg47His variant in a patient with posterior AD 
pathology. Although we did not have further clinical information on this subject, posterior AD is the 
pathology characteristic of PCA patients based on prior reports and reported subjects with both 
clinical and pathologic data (Carrasquillo et al., 2014; Crutch et al., 2012). The pathogenicity of the 
TREM2 Arg47His variant has been previously validated by replication of its association in numerous 
AD case-controls series (Guerreiro and Hardy, 2013; Jonsson et al., 2013) and by functional 
molecular studies (Kleinberger et al., 2014). One of the initial studies on TREM2 association with 
AD risk (Guerreiro and Hardy, 2013) included pathology descriptions for the TREM2 Arg47His 
variant and reported typical AD neuropathology. Given this and the role of this variant in AD risk, it 
is unlikely that TREM2 Arg47His is driving the posterior distribution of AD pathology. Rather, it is 
likely that this variant is involved in pathways common to both typical AD and PCA, with other 
genetic and/or environmental factors influencing vulnerability of posterior regions in some subjects.  
The PSEN2 Ser130Leu identified in our NeuroX screen has likewise not been previously 
reported in a PCA patient. However, a different PSEN2 variant (Met239Ile) was previously reported 
in a PCA case report (Tremolizzo et al., 2014). Others have argued that PSEN2 Ser130Leu is a 
benign variant (Sassi et al., 2014; Wojtas et al., 2012), based on its presence in 1 control out of 179 
(MAF=0.005) and the fact that this amino acid change is localized in the hydrophilic loop 1 in which 
deterministic AD mutations have not been reported. However, this variant is predicted to be possibly 
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damaging by Polyphen2 (Adzhubei et al., 2013), and was only observed in 9 out of 8591 European-
American population controls from the ESP (PSEN2 Ser130Leu, ESP control MAF=0.001), which is 
even lower than that reported in ESP controls for the TREM2 Arg47His variant (MAF=0.0026). It is 
possible that like TREM2 Arg47His, and unlike the Mendelian PSEN2 mutations, PSEN2 Ser130Leu 
is a risk, and not a deterministic variant, for both typical AD and PCA. Molecular studies will be 
needed to test the effect of the PSEN2 Ser130Leu variant on functional outcomes including APP 
processing. 
Although the association of the TREM2 Arg47His and PSEN2 Ser130Leu variants with PCA 
risk does not reach significance given their rarity, they appear to be enriched in the PCA cohort vs. 
population controls from ESP. It should be noted that both subjects with these variants have APOE 
ε3/ε4 genotype. The potential interaction of APOE ε4 with either rare variant in leading to PCA 
remains to be established, however at least for the subject with PSEN2 Ser130Leu variant, the 
presence of two pathogenic variants likely led to the very early age at onset at 38.     
We acknowledge that analyzing jointly the clinical PCA and posterior AD cases may 
introduce heterogeneity into our analyses because many of the posterior AD cases lack clinical 
information thus raising possibility that some of the posterior AD subjects might not have fit a 
clinical diagnosis of PCA. However, the correlation between a clinical diagnosis of PCA and a 
neuropathology classification of posterior AD has been published by several other groups, noting a 
very high (80-100%) concordance rate (Ala et al., 1996; Alladi et al., 2007; Renner et al., 2004; 
Tang-Wai et al., 2004; Victoroff et al., 1994). Also, in a previous publication (Carrasquillo et al., 
2014), we demonstrated that there are no significant differences between clinical PCA and posterior 
AD cases, in terms of percentage of affected females or the direction of risk association with APOE 
ε4, APOE ε2, CLU or BIN alleles. Therefore, we have analyzed clinical PCA and posterior AD cases 
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jointly, as this study design provides more power to detect PCA risk factors, by increasing the 
sample size. 
In addition to the results on this first pathogenic dementia variant screen in PCA, our study 
also provides another application for the customized array NeuroX, which includes exome content 
on variants selected from 12,000 individual exome and whole genomes (Grove et al., 2013), as well 
as custom content based on mutations or variants associated with neurological diseases, including 
AD and FTD GWAS hits, rare variants with large effect sizes, and rare variants identified through 
exome sequencing studies (Nalls et al., 2015). Although NeuroX could potentially lack rare, novel 
PCA susceptibility variants, it is an efficient platform for evaluating the effect of known putative 
functional variation, as its content represents ~95% of the known exome variants. That said, caution 
needs to be exercised in interpreting the results of NeuroX, as we and others (Ghani et al., 2015) 
determined an error in assay design/annotation for the GRN Gln130fs variant, which in fact denotes a 
non-pathogenic synonymous variant (rs25646). Further, assays can be prone to failure, such as the 
APOE ε4 (rs429358) pathogenic variant, which could lead to inability to assess all possible coding 
mutations in genes of interest.  
 In summary, in the present study we demonstrate that some of the coding variability in 
TREM2 and PSEN2 that has been previously implicated in AD is also present in posterior AD and 
PCA cases, respectively, hence expanding the mutation spectrum for this condition. We also validate 
the APOE ε4 association that we reported previously. Taken together with our previous finding of 
the association of AD GWAS loci with PCA risk (Carrasquillo et al., 2014), our studies provide 
novel information towards elucidating the genetic underpinnings of this disease by identifying 
specific genetic variants that are common to AD and PCA. Further investigation is needed to identify 
genetic factors that preferentially influence the vulnerability of posterior regions in PCA. Studies 
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that investigate the newer AD risk loci (Lambert et al., 2013) as well as novel genes and variants 
should prove invaluable towards the refinement of our understanding of PCA pathophysiology and 
future treatments.  
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TABLES 
Table 1. Cohort Description 
Group No. 
Female, n 
(%) 
APOE ε4 copies 0/1/2 
(%)a 
Mean age +/- SD 
(range)b 
Clinical PCA 67 43 (64%) 35/24/8 (52.2/35.8/11.9) 61.6 ± 8.5 (42-83) 
Posterior AD 
pathology 57 42 (74%) 16/30/11 (28.1/52.6/19.3) 80.0 ± 10.4 (58-99) 
Combined 
cases 124 85 (69%) 51/54/19 (41.1/43.5/15.3) 70.0 ± 13.2 (42-99) 
pc  0.26d 0.01d < 0.0001e 
 
Demographics for cases clinically diagnosed as PCA, pathologically diagnosed as Posterior AD, and 
combined cases are shown. a. The number of subjects with no, one or two copies of APOE ε4 allele 
(percentage of subjects); b. Age at onset is used for subjects recruited by clinical diagnosis and age 
at death is used for autopsied samples; c. Comparisons are between PCA and Posterior AD cases. d. 
P values for chi-square test; e. P value for two-sided, unpaired t-test. 
 Table 2. Number of variants per gene of interest in NeuroX. 
 Pathogenic Nature Unclear Pathogenic 
Source Gene Database 
Designed 
on 
NeuroX 
Worked 
on 
NeuroX 
Database 
Designed 
on 
NeuroX 
Worked 
on 
NeuroX 
Database 
Designed 
on 
NeuroX 
Worked 
on 
NeuroX 
From the 
AD&FTD 
Mutation 
Database 
APP 31 9 9 1 1 1 24 6 6 
PSEN1 197 77 76 8 4 4 185 70 69 
PSEN2 25 10 10 7 3 3 13 6 6 
GRN 149 32 32 35 10 10 69 12 12 
MAPT 73 11 11 2 0 0 44 1 1 
HPPa PRNP 42 5 5 0 0 0 24 1 1 
AD riskb 
APOE 2 2 1 0 0 0 2 2 1 
TREM2 1 1 1 0 0 0 1 1 1 
Total 8 520 147 145 53 18 18 362 99 97 
Variants listed are SNPs or small indels (duplication not included). Pathogenicity annotation per the AD&FTDMDB (molgen.vib-
ua.be/Public/MutationDatabase/Default.cfm) or the ahuman prion point mutations listed in http://www.madcow.org/prion_point_ 
mutations.html). bAD risk variants with confirmed pathogenicity (Guerreiro and Hardy, 2013; Kleinberger et al., 2014; Yu et al., 
2014).  
Table 3. Rare NeuroX pathogenic variants or of pathogenic nature unclear that are present in at least one case subject. 
 Fisher’s Exact Test a 
Gene 
Amino 
acid 
change 
dbSNP 
variant ID 
NeuroX        
variant 
name 
Minor 
allele 
count - 
Cases 
Major 
allele 
count - 
Cases 
Minor 
allele 
count - 
Controls 
(EVS) 
Major 
allele 
count - 
Controls 
(EVS) 
P OR LCI UCI 
PSEN2 Ser130Leu rs63750197 exm153953 1 247 9 8591 0.248 3.86 0.09 28.04 
TREM2 Arg47His  rs75932628 exm545529 1 247 22 8578 0.480 1.58 0.04 9.84 
Pathogenic variants or variants of "pathogenic nature unclear" (according to the AD&FTDMDB) that were present in at 
least one case subject are listed along with the results from a aFisher's exact test comparing allele frequencies in the 124 
PCA cases versus the frequency in 4,300 European Americans, according to the Exome Variant Server (EVS). P, Fisher's 
exact p-value; OR, odds ratio; LCI, lower 95% confidence interval; UCI, upper 95% confidence interval.  
FIGURE LEGENDS  
Figure 1. Sequence chromatograms from the carriers of the (a) PSEN2 Ser130Leu and (b) 
TREM2 Arg47His variants. In both panel (a) and (b), the variant site is indicated by the black 
arrow in the upper chromatogram, while the sequence from a control sample lacking the variant is 
shown in the lower chromatogram. 
Figure 2. Neuropathologic features of the TREM2 Arg47His carrier and typical AD 
neuropathology for comparison.  (a) cortical atrophy on lateral view (slight occipital 
predominance), (b) medial view demonstrating the occipital atrophy, (c) thioflavin-S fluorescent 
microscopic images of Brodmann area 18, (d) middle frontal gyrus, (e) hippocampal CA1 sector and 
(f) basal nucleus of Meynert. Figures 2 (g-j) correspond to the same regions as in (c-f), respectively, 
but are from an autopsied subject with typical AD neuropathology. Scale bar in (c) is 50 microns; 
scale bar in (f) is 20 microns (applies to d, e and f). The same magnifications are utilized for the 
corresponding figures (g-j).  
 
 


